Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial

OBJECTIVE: To evaluate the clinical efficacy and safety of leflunomide (L) added to the standard-of-care (SOC) treatment in COVID-19 patients hospitalised with moderate/critical clinical symptoms. DESIGN: Prospective, open-label, multicentre, stratified, randomised clinical trial. SETTING: Five hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kralj-Hans, Ines, Li, Kuo, Wesek, Adrian, Lamorgese, Alexia, Omar, Fatima, Ranasinghe, Kapila, McGee, Megan, Brack, Kieran, Li, Shiliang, Aggarwal, Ritesh, Bulle, Ajay, Kodre, Aparna, Sharma, Shashank, Fluck, David, John, Isaac, Sharma, Pankaj, Belsey, Jonathan D, Li, Ling, Seshasai, Sreenivasa Rao Kondapally, Li, Hong Lin, Marczin, Nandor, Chen, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105917/
https://www.ncbi.nlm.nih.gov/pubmed/37055207
http://dx.doi.org/10.1136/bmjopen-2022-068179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105917/
https://www.ncbi.nlm.nih.gov/pubmed/37055207
http://dx.doi.org/10.1136/bmjopen-2022-068179

Ejemplares similares